IDH1 MUTATION IS AN IMPORTANT FACTOR PREDICTING OUTCOME IN HIGH GRADE GLIOMAS

被引：0
|
作者：
Perez-Magan, E. [1 ]
Ruano, Y. [1 ]
Garcia-Claver, A. [1 ]
Juarez, R. [1 ]
Ferrara, P. [1 ]
Fiano, C. [2 ]
Ribalta, T. [3 ]
Mollejo, M. [1 ]
Rodriguez de Lope, A. [1 ]
Melendez, B. [1 ]
机构：
[1] Hosp Virgen Salud, Toledo, Spain
[2] Complejo Hosp Xeral Cies, Vigo, Spain
[3] Hosp Clin Barcelona, Barcelona, Spain
来源：
NEURO-ONCOLOGY | 2010年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [21] IDH1 Mutation-Inspired α-Ketoglutaric Acid Mimics for Epigenetic Therapy of Higher Grade Gliomas
    Madala, H.
    Punganuru, S.
    Srivenugopal, K.
    AMERICAN JOURNAL OF PATHOLOGY, 2017, 187 (10): : 2353 - 2354
  • [22] Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status
    Makoto Ohno
    Yoshitaka Narita
    Yasuji Miyakita
    Yoshiko Okita
    Yuko Matsushita
    Akihiko Yoshida
    Shintaro Fukushima
    Koichi Ichimura
    Takamasa Kayama
    Soichiro Shibui
    Brain Tumor Pathology, 2012, 29 : 183 - 191
  • [23] Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status
    Ohno, Makoto
    Narita, Yoshitaka
    Miyakita, Yasuji
    Okita, Yoshiko
    Matsushita, Yuko
    Yoshida, Akihiko
    Fukushima, Shintaro
    Ichimura, Koichi
    Kayama, Takamasa
    Shibui, Soichiro
    BRAIN TUMOR PATHOLOGY, 2012, 29 (04) : 183 - 191
  • [24] IDH1 mutation-inspired α-ketoglutaric acid mimics for epigenetic therapy of higher grade gliomas
    Madala, Hanumantha Rao
    Punganuru, Surendra Reddy
    Srivenugopal, Kalkunte S.
    CANCER RESEARCH, 2017, 77
  • [25] CHARACTERIZATION OF DIFFERENTIAL 5-HYDROXYMETHYLCYTOSINE IN IDH1 MUTANT VERSUS IDH1 WILD-TYPE HIGH-GRADE GLIOMAS
    Glowacka, Wioletta
    Jain, Harshika
    Okura, Makiko
    Maimaitiming, Abulizi
    Yasin, Mamatjan
    Farooq, Hamza
    Aldape, Kenneth
    Kongkham, Paul
    NEURO-ONCOLOGY, 2017, 19 : 95 - 95
  • [26] LIMITS OF IMMUNOHISTOCHEMISTRY IN DETECTION OF IDH1 MUTATIONS IN LOW GRADE GLIOMAS
    Jancalek, Radim
    Hermanova, Marketa
    Slaby, Ondrej
    NEURO-ONCOLOGY, 2017, 19 : 181 - 181
  • [27] Limits of immunohistochemistry in detection of IDH1 mutations in low grade gliomas
    Jancalek, R.
    Slaby, O.
    Hermanova, M.
    Brichtova, E.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 388 - 388
  • [28] Predictive impact of IDH1 or IDH2 mutations on outcome and response to temozolomide in low-grade gliomas.
    Houillier, C.
    Wang, X.
    Kaloshi, G.
    Mokhtari, K.
    Laffaire, J.
    Boisselier, B.
    Idbaih, A.
    Hoang-Xuan, K.
    Sanson, M.
    Delattre, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Molecular signatures classify astrocytic gliomas by IDH1 mutation status
    Toedt, Grischa
    Barbus, Sebastian
    Wolter, Marietta
    Felsberg, Joeg
    Tews, Bjoern
    Blond, Frederic
    Sabel, Michael C.
    Hofmann, Stefanie
    Becker, Natalia
    Hartmann, Christian
    Ohgaki, Hiroko
    von Deimling, Andreas
    Wiestler, Otmar D.
    Hahn, Meinhard
    Lichter, Peter
    Reifenberger, Guido
    Radlwimmer, Bernhard
    INTERNATIONAL JOURNAL OF CANCER, 2011, 128 (05) : 1095 - 1103
  • [30] Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing
    Shingo Takano
    Wei Tian
    Masahide Matsuda
    Tetsuya Yamamoto
    Eiichi Ishikawa
    Mika Kato Kaneko
    Kentaro Yamazaki
    Yukinari Kato
    Akira Matsumura
    Brain Tumor Pathology, 2011, 28 : 115 - 123
12345